

BUY Oil India

Your success is our success

One-time provision hits steady core performance; retain BUY

Oil & Gas ▶ Result Update ▶ November 9, 2023

TARGET PRICE (Rs) : 370

OIL reported a 9% beat in Q2FY24 S/A adj. EBITDA at Rs26.3bn, led by 4% revenue beat on higher sales to production ratio and lower opex, while APAT stood at Rs20.2bn, a 16% beat accentuated by higher other income. RPAT, however, slumped to Rs3.3bn due to a one-time provision of Rs23.6bn for GST on royalty, similar to ONGC (in Q4FY23). Crude production was in-line at 0.83mmt (up 6% YoY), while gas was 3% beat at 0.81bcm (down 2% YoY). NRL's operations resumed post the shutdown; with more than 100% utilization and basic GRM up to USD16.0/bbl in Q2, earnings recovered to Rs7.4bn. Mgmt. cited crude production target at 3.5-3.6mmtpa for FY24, while gas could see 2-3% YoY growth. We raise our consol. adj. EPS for FY24/25E by 13%/7% to build-in lower opex and H1FY24 runrate. We hike our Sep-24 TP by 12% to Rs370 on roll-over and lower opex going ahead. We retain our BUY rating.

Oil India: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	3,00,112	4,10,389	2,91,804	3,00,391	3,11,370
EBITDA	1,05,004	1,52,681	1,10,602	1,16,716	1,15,315
Adj. PAT	56,216	87,286	66,414	69,607	68,779
Adj. EPS (Rs)	51.8	80.5	61.2	64.2	63.4
EBITDA margin (%)	35.0	37.2	37.9	38.9	37.0
EBITDA growth (%)	84.6	45.4	(27.6)	5.5	(1.2)
Adj. EPS growth (%)	42.3	55.3	(23.9)	4.8	(1.2)
RoE (%)	20.7	25.3	17.9	14.7	13.4
RoIC (%)	41.2	59.5	42.6	38.3	34.5
P/E (x)	5.8	3.7	4.9	4.7	4.8
EV/EBITDA (x)	4.5	3.1	4.4	4.4	4.5
P/B (x)	1.1	0.8	0.7	0.7	0.6
FCFF yield (%)	7.0	6.1	(11.8)	(3.8)	5.8

Source: Company, Emkay Research

Result Highlights

OIL's crude sales-to-production ratio jumped to 102% from 91% QoQ, while gas was also up to 80% from 73%. Crude realization for Q2FY24 stood at USD86.9/bbl. Gas realization was steady QoQ at ~USD7.0/mmmbtu. Employee costs rose 5% YoY/9% QoQ to Rs4.9bn, while other expenses increased 1% YoY/48% QoQ to Rs8.3bn (13% below estimates). DD&A was flat YoY but up 7% QoQ to Rs4.2bn. Interest costs rose 35% QoQ to Rs2.2bn (vs. Rs1.7bn estimated by us). Total statutory levies were 12% higher than estimates on account of inventory-related and other adjustment in windfall levy. NRL reported 1% YoY growth in EBITDA to Rs10.8bn, with volume at 0.78mmt (up 1% YoY). The share of loss from assoc./JV in consol. accounts was Rs541mn in Q2FY24 vs. Rs957mn profit in Q1. Consol. adj. EPS for Q2 was up 18% YoY/56% QoQ at Rs20.6/share. The board has recommended an interim dividend of Rs3.5/share.

Management KTAs

OIL accounted for GST provision on royalty on account of prudence and conservatism, while the Gauhati HC hearing has also been deferred. The recurring run-rate of this provision is Rs5bn p.a. Gas production fell in H1 due to lower customer offtake. Mgmt. refrained from giving guidance beyond FY24 but intends production CAGR of 4-5% for the next 2-3 years. NRL's recent rights issue covers the entire equity infusion requirement from OIL for the expansion project. OIL may have declared a higher interim dividend, if GST on royalty provision was not made in Q2; while a higher second interim dividend might be possible. Out of OIL's total consol. capex plan of more than Rs130bn for FY24E, Rs49bn would be on standalone and Rs87bn towards NRL. Out of the total NRL expansion capex of Rs280bn, Rs130bn has been spent till Sep-23 end and the balance will be incurred by FY25-end. Russian dividends stuck are ~USD450mn as of now. OIL's consol. debt was Rs200bn as of Sep-23 end, split between OIL SA-ECB/Singapore subsidiary/NRL as Rs110/40/56.5bn.

Valuation

We value OIL on an SOTP basis, comprising S/A (using DCF) and NRL (DDM). Investments are valued at our TP or CMP, with a 30% holdco discount. Key risks: Adverse oil and gas prices, policy issues, local tensions, cost overruns, outages, & dry holes.

Target Price – 12M	Sep-24
Change in TP (%)	12.2
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	22.8
CMP (09-Nov-23) (Rs)	301.6

Stock Data	Ticker
52-week High (Rs)	339
52-week Low (Rs)	193
Shares outstanding (mn)	1,084.4
Market-cap (Rs bn)	327
Market-cap (USD mn)	3,927
Net-debt, FY24E (Rs mn)	1,58,278
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	683.6
ADTV-3M (USD mn)	8.2
Free float (%)	33.0
Nifty-50	19,395
INR/USD	83.3
Shareholding, Sep-23	
Promoters (%)	56.7
FPIs/MFs (%)	11.3/15.9

Price Performance

(%)	1M	3M	12M
Absolute	(3.1)	9.1	53.8
Rel. to Nifty	(2.5)	10.4	44.0

1-Year share price trend (Rs)**Sabri Hazarika**

sabri.hazarika@emkayglobal.com
+91 22 6612 1282

Harsh Maru

harsh.maru@emkayglobal.com
+91 22 6612 1336

Arya Patel

arya.patel@emkayglobal.com
+91 22 6612 1285

Exhibit 1: Actuals vs. Estimates (Q2FY24)

Standalone (Rs mn)	Actual	Estimates (Emkay)	Consensus Estimates (Bloomberg)	Variation		Comments
				Emkay	Consensus	
Total Revenue	59,133	56,636	55,861	4%	6%	Higher sales to production, gas vol.
Adjusted EBITDA	26,349	24,186	23,063	9%	14%	Lower opex and provisions
EBITDA Margin (%)	44.6%	42.7%	41.3%	186bps	327bps	
Adjusted Net Profit	20,176	17,430	14,300	16%	41%	Higher other income

Source: Company, Emkay Research

Exhibit 2: Quarterly Summary

Rs mn (S/A)	Q2FY23	Q3FY23	Q4FY23	Q1FY24	Q2FY24	YoY	QoQ	H1FY23	H1FY24	YoY
Revenue	57,729	58,794	56,462	46,447	59,133	2%	27%	1,17,370	1,05,580	-10%
COGS+OPEX	12,850	11,386	18,378	9,776	12,569	-2%	29%	29,198	22,345	-23%
Statutory Levies	25,112	18,686	15,399	13,382	20,215	-20%	51%	41,548	33,597	-19%
Survey + Dry Wells	1,316	170	-791	-	-			1,844	-	
EBITDA	18,451	28,553	23,476	23,289	26,349	43%	13%	44,780	49,638	11%
DD&A	4,236	4,536	3,309	3,974	4,234	0%	7%	8,104	8,208	1%
EBIT	14,215	24,017	20,167	19,315	22,116	56%	15%	36,676	41,431	13%
Finance Charges	2,113	2,010	1,077	1,659	2,235	6%	35%	4,155	3,894	-6%
Other Income	8,979	1,022	4,294	3,341	7,092	-21%	112%	9,637	10,433	8%
Exceptional Items	-	-	-	-	-25,091			-	-25,091	
PBT	21,081	23,029	23,383	20,997	1,882	-91%	-91%	42,158	22,878	-46%
Total Tax	3,876	5,568	5,501	4,863	-1,372			9,398	3,491	-63%
PAT	17,205	17,461	17,883	16,134	3,253	-81%	-80%	32,760	19,387	-41%
Adjusted PAT	17,205	17,461	17,883	16,134	20,176	17%	25%	32,760	36,310	11%
Adjusted EPS (Rs)	15.9	16.1	16.5	14.9	18.6	17%	25%	30.2	33.5	11%
Crude Production (mmt)	0.79	0.81	0.80	0.82	0.84	6%	2%	1.57	1.66	6%
Gas Production (bcm)	0.82	0.81	0.78	0.75	0.81	-2%	9%	1.59	1.56	-2%
NB Gross Oil Realization (USD/bbl)	100.6	88.3	82.4	76.9	86.9	-14%	13%	106.7	81.9	-23%
NB Net Oil Realization (USD/bbl)	100.6	88.3	82.4	76.9	86.9	-14%	13%	106.7	81.9	-23%
NB Gas Realization (Rs/scm)	18.1	25.8	26.1	20.5	20.5	13%	0%	17.7	20.5	16%
Net Debt	85,285		96,460		78,943			85,285	78,943	-7%
CFS Capex (Half Yearly)	14,688		34,137		18,874			14,688	18,874	28%
NRL Volumes (mmt)	0.77	0.80	0.73	0.07	0.78	1%		1.56	0.85	-46%
NRL Basic GRMs (USD/bbl)	13.8	13.5	20.4	-15.6	16.0	16%		23.2	13.4	-42%
NRL Reported EBITDA	10,697	11,218	11,398	-52	10,846	1%		30,579	10,794	-65%
NRL Reported PAT	7,278	7,991	7,692	-776	7,355	1%		21,344	6,580	-69%
NRL Capex (PPAC)	15,968	13,615	24,728	15,950	18,920			27,807	34,870	25%

Source: Company, Emkay Research; Note: Adjusted PAT may not fully match the annual tables due to a different adjustment method in the Emkay detailed annual model.

Exhibit 3: Change in estimates

Consolidated (Rs mn)	FY24E			FY25E			FY26E Introduced
	Previous	Revised	Variance	Previous	Revised	Variance	
Revenue	2,89,046	2,91,804	1%	2,99,397	3,00,391	0%	3,11,370
EBITDA	99,807	1,10,602	11%	1,08,995	1,16,716	7%	1,15,315
EBITDA Margins	34.5%	37.9%	337bps	36.4%	38.9%	245ps	37.0%
APAT	58,968	66,414	13%	64,951	69,607	7%	68,779
Adj. EPS (Rs)	54.4	61.2	13%	59.9	64.2	7%	63.4

Source: Company, Emkay Research

Concall Highlights

Q2FY24 Performance

- OIL accounted for GST provision on royalty on account of prudence and conservatism. The Gauhati High Court hearing has also been deferred on the same. OIL will continue to make these provisions with an annualized run-rate of Rs5bn, while H1FY24 provision was Rs2.93bn. GST rate on royalty is 18%.
- Gross crude realization of OIL stood at USD86.86/bbl in Q2FY24, while windfall-adjusted net realization was steady at USD75-76/bbl. Windfall per unit rate may seem higher due to periodic inventory-related and other adjustments, but net realization should be ~USD75/bbl. Seismic cost was Rs1.1bn/1.5bn/1.05bn in Q2FY24/Q1FY24/Q2FY23. There was no opex rise in NRL.
- OIL has not made any dry well write-offs in Q2FY24, while provisions were just Rs20-30mn. OIL's other income included dividend income from NRL/IOCL/Singapore subsidiary (Russian investment holdco) amounting to Rs1.6/2.2/4bn. In case of NRL and IOCL, the final dividend of FY23 was received. Other income was lower YoY due to NRL dividend difference (lower by) of Rs4bn.
- OIL's consolidated debt stood at Rs200bn as of Sep-23 end and is split between OIL standalone-ECB/Singapore subsidiary/NRL as Rs110/40/56.5bn. Interest cost in Q2FY24 included forex gain of Rs380mn; hence, it is looking optically higher on a QoQ basis.

Outlook

- OIL's MOU targets for FY24 were 3.8mmtpa crude oil and 3.8bcm natural gas, though, in actuality, crude should be 3.5-3.6mmtpa (FY24 end). On the gas front, production fell in H1 due to the offtake issue on account of customer plant shutdowns in NRL, BCPL etc. However, it still expects gas production to grow by 2-4% YoY in FY24. Management has refrained from giving guidance beyond FY24, but said that it intends production CAGR of 4-5% for the next 2-3 years.
- Out of OIL's total consolidated capex plan of Rs130bn+ for FY24E, Rs49bn is attributable to the standalone business and the balance Rs87bn is towards NRL. Out of the total NRL expansion capex of Rs280bn, Rs130bn has been spent till Sep-23 end and the balance will be incurred by FY25-end. Capex for domestic E&P is expected to be Rs45-50bn p.a. for the next two years. NRL maintenance capex could be Rs3-4bn p.a. (a few hundred crores).
- OIL has not made any new discoveries outside India. The company does not have any new plans or acquisitions, etc. as of now. Mozambique is the only project under development while Russian assets are already operational. OIL has also not made any new discoveries in India in H1FY24, though it plans to maintain RRR of 1+ and carry out activities. OIL has completed geological studies in the Andaman cluster and exploratory drilling is planned to be commenced from Jun-Jul 2024.

International Projects

- OIL does not plan to make additional investments in the Russian assets; while operational performance for both is in line with estimates (Taas is better than the target of 5mmtpa). Sale of Russian crude is capped; hence, realizations are lower in Russian assets.
- In terms of Mozambique, OIL has invested USD1.4bn out of the total board-approved figure of USD1.8bn. Once force majeure is lifted (work is going on for the same), funding would be available through the ECL route and equity requirements may be reduced for partners.
- Venezuela is witnessing positive traction; however, development work has not started in OIL's block (weak output). It awaits more clarity in the coming 1-2 quarters, while additional investment would commence once activities start. OIL has invested USD60mn till date out of the total plan of USD425mn.
- Singapore subsidiary paid out dividends from funds received prior to the payment embargo; while money stuck in terms of Russian dividends is ~USD450mn as of now.

Others

- NRL's recent rights issue covers the entire equity infusion requirement from OIL for the expansion project. OIL has paid the first call viz. 25% of the right issue amount to date and the balance will be invested as and when calls are made. Other partners of NRL have also made their contributions.
- OIL may have declared a higher interim dividend if GST on royalty provision was not made in Q2, though YoY payout was still better. However, a higher second interim dividend can be possible. OIL intends to follow DIPAM guidelines on dividend payout viz. higher of 30% of profits or 5% of net worth. The company will try to meet dividend expectations.
- OIL does not expect additional provisions relating to Baghjan for now and the recent NGT report does not mandate anything for OIL, rather it has issued directives to PCB, agencies etc. No commitment is there from OIL's side.
- OIL has not received any update from DGH on the premium pricing of gas from new wells.

Exhibit 4: Oil India – Standalone DCF-based valuation

Assumptions		Standalone	Rs mn
Risk-Free Rate	7.0%	NPV Of FCF (Sep-25–Sep-36)	2,33,131
Risk Premium	5.3%	Terminal Value	1,86,322
Beta	0.81	PV Of TV	56,111
Cost Of Equity	11.3%	Total Value	2,89,242
Cost Of Debt	7.5%	Less: Net Debt (Mar-23E)	73,682
Post Tax Cost Of Debt	5.6%	Equity Value	2,15,560
Average Debt:Equity Ratio	15.0%	No. Of Shares O/S (mn)	1,084
WACC	10.5%	Fair Value of Oil India S/A (Rs/sh)	199
Terminal Growth Rate	0.0%		

Source: Company, Emkay Research

Exhibit 5: NRL – Standalone DDM Valuation

Assumptions		Standalone	Rs mn
Risk-Free Rate	7.0%	Value of Explicit Period Dividend	94,973
Risk Premium	5.3%	Terminal Value	2,34,937
Beta	0.81	PV of TV	74,956
Cost Of Equity	11.3%	Total Value	1,69,930
Cost Of Debt	8.5%	Oil India's Value	1,18,322
Post Tax Cost Of Debt	6.4%	Value/Share (Rs)	109
Average Debt:Equity Ratio	35.0%		
WACC	10.0%		
Terminal Growth Rate	0.0%		

Source: Company, Emkay Research

Exhibit 6: SOTP Valuation – Sep-24E

Components (Rs mn)	Basis	Sep-24 Eq. Val	Value/Sh (Rs)	Comments
Oil India Standalone	DCF	2,05,161	189	WACC/TG at 10.5%/0%
NRL (69.6% Stake)	DDM	1,22,227	113	WACC/TG at 10%/0%
Mozambique Upside	DCF	-	-	
Core Business Valuation		3,27,389	302	
Value of Investments	TP/BV	74,165	68	At 30% Holdco Discount
Target Price-Fair Value		4,01,554	370	

Source: Company, Emkay Research

Exhibit 7: Schedule and value of investments (Sep-24E Valuation)

Listed + Unlisted	Type	Basis of Valuation	TP/CMP (Rs/sh)	Equity Value (Rs bn)	Oil India Stake	Pro-rata Value (Rs bn)	Holdco Discount	Contr. to SOTP (Rs bn)	Per Share Value (Rs)
IOCL	Financial	TP (Emkay)	100	1,377	5.2%	71	30%	50	46
OIL International Pte (Russia)	Subsidiary	BV		35	100.0%	35	30%	24	23
Total						106		74	68

Source: Company, Emkay Research

Oil India : Consolidated Financials and Valuations

Profit & Loss					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Revenue	3,00,112	4,10,389	2,91,804	3,00,391	3,11,370
Revenue growth (%)	33.5	36.7	(28.9)	2.9	3.7
EBITDA	1,05,004	1,52,681	1,10,602	1,16,716	1,15,315
EBITDA growth (%)	84.6	45.4	(27.6)	5.5	(1.2)
Depreciation & Amortization	18,245	19,469	22,921	25,707	27,077
EBIT	86,759	1,33,211	87,681	91,010	88,238
EBIT growth (%)	125.7	53.5	(34.2)	3.8	(3.0)
Other operating income	11,426	7,194	15,407	17,859	17,730
Other income	11,426	7,194	15,407	17,859	17,730
Financial expense	9,401	9,009	8,391	8,054	6,553
PBT	88,784	1,31,396	94,697	1,00,815	99,415
Extraordinary items	0	0	(8,521)	0	0
Taxes	22,710	32,895	15,342	25,405	25,053
Minority interest	10,976	11,258	4,934	6,343	6,151
Income from JV/Associates	1,119	43	515	541	568
Reported PAT	56,216	87,286	66,414	69,607	68,779
PAT growth (%)	42.3	55.3	(23.9)	4.8	(1.2)
Adjusted PAT	56,216	87,286	66,414	69,607	68,779
Diluted EPS (Rs)	51.8	80.5	61.2	64.2	63.4
Diluted EPS growth (%)	42.3	55.3	(23.9)	4.8	(1.2)
DPS (Rs)	14.2	20.0	12.6	22.6	22.5
Dividend payout (%)	27.5	24.8	20.5	35.3	35.4
EBITDA margin (%)	35.0	37.2	37.9	38.9	37.0
EBIT margin (%)	28.9	32.5	30.0	30.3	28.3
Effective tax rate (%)	25.6	25.0	16.2	25.2	25.2
NOPLAT (pre-IndAS)	64,567	99,862	73,475	68,075	66,002
Shares outstanding (mn)	1,084.4	1,084.4	1,084.4	1,084.4	1,084.4

Source: Company, Emkay Research

Cash flows					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
PBT	88,784	1,31,396	94,697	1,00,815	99,415
Others (non-cash items)	27,475	37,185	15,390	15,360	15,333
Taxes paid	(10,362)	(33,422)	(15,342)	(25,405)	(25,053)
Change in NWC	(13,920)	(21,097)	4,202	(14,248)	21,842
Operating cash flow	93,096	1,14,104	75,319	76,523	1,11,537
Capital expenditure	(59,680)	(85,246)	(1,32,771)	(95,875)	(81,772)
Acquisition of business	0	0	0	0	0
Interest & dividend income	7,687	5,059	15,407	17,859	17,730
Investing cash flow	(41,931)	(91,314)	(71,040)	(82,413)	(80,484)
Equity raised/(repaid)	0	0	0	0	0
Debt raised/(repaid)	(34,990)	7,095	13,283	48,400	(10,000)
Payment of lease liabilities	(935)	(935)	(935)	(935)	(935)
Interest paid	(7,061)	(8,266)	(8,391)	(8,054)	(6,553)
Dividend paid (incl tax)	(13,809)	(24,940)	(13,626)	(24,545)	(24,358)
Others	4,331	22,412	2,142	(572)	5,927
Financing cash flow	(51,528)	(3,700)	(6,593)	15,230	(34,984)
Net chg in Cash	(364)	19,090	(2,314)	9,340	(3,931)
OCF	93,096	1,14,104	75,319	76,523	1,11,537
Adj. OCF (w/o NWC chg.)	79,176	93,007	79,521	62,275	1,33,379
FCFF	33,416	28,859	(57,452)	(19,352)	29,765
FCFE	31,701	24,909	(50,436)	(9,547)	40,942
OCF/EBITDA (%)	88.7	74.7	68.1	65.6	96.7
FCFE/PAT (%)	56.4	28.5	(75.9)	(13.7)	59.5
FCFF/NOPLAT (%)	51.8	28.9	(78.2)	(28.4)	45.1

Source: Company, Emkay Research

Balance Sheet					
Y/E Mar (Rs mn)	FY22	FY23	FY24E	FY25E	FY26E
Share capital	10,844	10,844	10,844	10,844	10,844
Reserves & Surplus	2,94,775	3,73,971	4,42,212	4,85,625	5,23,028
Net worth	3,05,619	3,84,815	4,53,056	4,96,469	5,33,872
Minority interests	26,143	33,711	38,645	44,988	51,140
Deferred tax liability (net)	31,449	33,178	31,856	33,063	34,149
Total debt	1,67,205	1,88,318	2,01,600	2,50,000	2,40,000
Total liabilities & equity	5,30,417	6,40,021	7,25,157	8,24,520	8,59,161
Net tangible fixed assets	1,52,017	1,64,699	1,64,342	1,77,682	2,00,760
Net intangible assets	2,093	2,093	2,093	2,093	2,093
Net ROU assets	3,681	3,681	3,681	3,681	3,681
Capital WIP	69,258	1,30,040	2,16,551	2,73,381	3,04,997
Goodwill	0	0	0	0	0
Investments [JV/Associates]	2,81,966	2,92,934	2,95,862	3,02,025	3,08,328
Cash & equivalents	19,368	41,430	43,322	62,593	50,089
Current assets (ex-cash)	79,799	1,03,953	91,431	1,24,728	91,791
Current Liab. & Prov.	77,766	98,809	92,125	1,21,662	1,02,579
NWC (ex-cash)	2,033	5,144	(694)	3,066	(10,788)
Total assets	5,30,417	6,40,021	7,25,157	8,24,520	8,59,161
Net debt	1,47,837	1,46,887	1,58,278	1,87,407	1,89,911
Capital employed	5,30,417	6,40,021	7,25,157	8,24,520	8,59,161
Invested capital	1,59,824	1,75,617	1,69,423	1,86,521	1,95,746
BVPS (Rs)	281.8	354.9	417.8	457.8	492.3
Net Debt/Equity (x)	0.5	0.4	0.3	0.4	0.4
Net Debt/EBITDA (x)	1.4	1.0	1.4	1.6	1.6
Interest coverage (x)	0.1	0.1	0.1	0.1	0.1
RoCE (%)	19.5	24.0	15.1	14.1	12.6

Source: Company, Emkay Research

Valuations and key Ratios					
Y/E Mar	FY22	FY23	FY24E	FY25E	FY26E
P/E (x)	5.8	3.7	4.9	4.7	4.8
P/CE(x)	4.4	3.1	3.3	3.4	3.4
P/B (x)	1.1	0.8	0.7	0.7	0.6
EV/Sales (x)	1.6	1.2	1.7	1.7	1.7
EV/EBITDA (x)	4.5	3.1	4.4	4.4	4.5
EV/EBIT(x)	5.5	3.6	5.5	5.7	5.9
EV/IC (x)	3.0	2.7	2.9	2.8	2.6
FCFF yield (%)	7.0	6.1	(11.8)	(3.8)	5.8
FCFE yield (%)	9.7	7.6	(15.4)	(2.9)	12.5
Dividend yield (%)	4.7	6.6	4.2	7.5	7.4
DuPont-RoE split					
Net profit margin (%)	18.7	21.3	25.7	23.2	22.1
Total asset turnover (x)	0.6	0.7	0.4	0.4	0.4
Assets/Equity (x)	1.9	1.7	1.6	1.6	1.6
RoE (%)	20.7	25.3	17.9	14.7	13.4
DuPont-RoIC					
NOPLAT margin (%)	21.5	24.3	25.2	22.7	21.2
IC turnover (x)	0.0	0.0	0.0	0.0	0.0
RoIC (%)	41.2	59.5	42.6	38.3	34.5
Operating metrics					
Core NWC days	37.2	40.8	40.3	50.2	36.5
Total NWC days	37.2	40.8	40.3	50.2	36.5
Fixed asset turnover	1.1	1.4	0.9	0.8	0.8
Opex-to-revenue (%)	65.0	62.8	62.1	61.1	63.0

Source: Company, Emkay Research

This report is intended for team.emkay@whitemarquesolutions.com use and downloaded at 11/27/2023 05:25 PM


Emkay Research is also available on www.emkayglobal.com and Bloomberg EMKAY<GO>. Please refer to the last page of the report on Restrictions on Distribution. In Singapore, this research report or research analyses may only be distributed to Institutional Investors, Expert Investors or Accredited Investors as defined in the Securities and Futures Act, Chapter 289 of Singapore.

RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (INR)	TP (INR)	Rating	Analyst
09-Aug-23	277	330	Buy	Sabri Hazarika
05-Jun-23	254	330	Buy	Sabri Hazarika
25-May-23	261	330	Buy	Sabri Hazarika
13-Feb-23	241	290	Buy	Sabri Hazarika
06-Dec-22	211	270	Buy	Sabri Hazarika
01-Dec-22	207	270	Buy	Sabri Hazarika
24-Nov-22	197	270	Buy	Sabri Hazarika
02-Oct-22	174	260	Buy	Sabri Hazarika
07-Sep-22	196	260	Buy	Sabri Hazarika
11-Aug-22	188	260	Buy	Sabri Hazarika
15-Jul-22	182	270	Buy	Sabri Hazarika
02-Jul-22	214	270	Buy	Sabri Hazarika
28-Jun-22	250	305	Buy	Sabri Hazarika
04-Jun-22	251	305	Buy	Sabri Hazarika
22-May-22	239	335	Buy	Sabri Hazarika
01-Apr-22	239	335	Buy	Sabri Hazarika
09-Mar-22	243	335	Buy	Sabri Hazarika
15-Feb-22	225	320	Buy	Sabri Hazarika
25-Dec-21	177	270	Buy	Sabri Hazarika
23-Nov-21	197	270	Buy	Sabri Hazarika
12-Nov-21	222	270	Buy	Sabri Hazarika
16-Sep-21	212	255	Buy	Sabri Hazarika
10-Sep-21	195	255	Buy	Sabri Hazarika
26-Jul-21	161	165	Hold	Sabri Hazarika
23-Jun-21	153	165	Hold	Sabri Hazarika
29-May-21	133	100	Hold	Sabri Hazarika
23-Apr-21	116	100	Hold	Sabri Hazarika
23-Mar-21	118	100	Hold	Sabri Hazarika
18-Feb-21	122	100	Hold	Sabri Hazarika
12-Feb-21	116	100	Hold	Sabri Hazarika
26-Nov-20	97	90	Hold	Sabri Hazarika
10-Nov-20	89	90	Hold	Sabri Hazarika

Source: Company, Emkay Research

RECOMMENDATION HISTORY - TREND



Source: Bloomberg, Company, Emkay Research

GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. www.emkayglobal.com.

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit www.emkayglobal.com to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

Disclaimer for U.S. persons only: Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons¹ may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests² in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

¹ An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

² Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 9, 2023
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report
Disclosure of previous investment recommendation produced:
- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 9, 2023
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 9, 2023
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	Over 15%
HOLD	Between -5% to 15%
SELL	Below -5%

Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: www.emkayglobal.com

OTHER DISCLAIMERS AND DISCLOSURES:**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) -:**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit www.emkayglobal.com to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.